Jefferies downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $56, down from $75, after Novo Nordisk (NVO) announced a deal to acquire Akero for up to $5.2B, including $4.7B upfront. The deal following Roche’s (RHHBY) purchase of 89bio (ETNB) and GSK (GSK) buying Boston Pharma signals “Big Pharma’s high interest in MASH,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics downgraded to Hold from Buy at Canaccord
- Akero Therapeutics rises 16.5%
- Video: Delta soars after earnings, lifts airline peers
- Morning Movers: Akero jumps after deal to be bought by Novo Nordisk
- M&A News: Akero Therapeutics Stock (AKRO) Zooms 19% after Novo Nordisk Buys it for $5.2B